方毅,王斌,李晶,裘淼涵,韩雅玲

• 1:沈阳军区总医院心血管内科

摘要(Abstract)：

目的比较国产涂层可降解与涂层不可降解西罗莫司(雷帕霉素)洗脱支架(sirolimuseluting stents,SES)在冠心病患者行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)中的有效性和安全性。方法选取2012年10月至2014年1月在沈阳军区总医院置入SES的冠心病患者2950例,其中涂层可降解SES组患者1520例,涂层不可降解SES组患者1430例。采用倾向评分配对分析对基线不匹配患者行1∶1匹配后得到倾向匹配队列,观察两组患者PCI术后主要不良心血管事件(major adverse clinical events,MACE,包括心源性死亡、非致死性心肌梗死、靶血管血运重建)和支架内血栓的发生率。结果随访1年,涂层可降解SES组和涂层不可降解SES组的MACE[85例(6.8%)比75例(6.0%),P=0.414]、心源性死亡[20例(1.6%)比18例(1.4%),P=0.744]、非致死性心肌梗死[28例(2.2%)比22例(1.8%),P=0.391]、靶血管血运重建[44例(3.5%)比36例(2.9%),P=0.363]、支架内血栓[14例(1.1%)比8例(0.6%),P=0.284]的发生率分别比较,差异均无统计学意义。结论国产涂层可降解与不可降解SES在冠状动脉疾病治疗中的近期疗效和安全性相似,其远期效果有待进一步研究。

关键词(KeyWords)： 药物洗脱支架;涂层可降解;涂层不可降解;西罗莫司

Abstract:

Keywords:

基金项目(Foundation): 军队临床高新技术重大项目(2010gxjs001);; 辽宁省科技攻关项目(2013225089)

作者(Author): 方毅,王斌,李晶,裘淼涵,韩雅玲

参考文献(References)：

• [1]Stone GW,Ellis SG,Cannon L,et al.Comparison of a polymerbased paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease:a randomized controlled trial.JAMA,2005,294(10):1215-1223.
• [2]Brunner La,Rocca HP,Kaiser C,et al.Cost-effectiveness of drug-eluting stents in patients at high or low risk of majorcardiac events in the Basel Stent Kosten Effektivitats Trial(BASKET):an 18-month analysis.Lancet,2007,370(9598):1552-1559.
• [3]Fere F,Costa JR,Abizaid A.Very late thrombosis after durgeluting stents.Catheter Cardiovasc Interv,2006,47(2):175-181.
• [4]Zhu L,Lv YN,Wang LY.Stent thrombosis with biodegradable polymer drug-eluting stents versus durable polymer sirolimuseluting stents:an update meta-analysis.Cardiology,2015,130(2):96-105.
• [5]Navarese EP,Kubica L,Castriota F,et al.Safety and efficacy of biodegradable vs.durable polymer drug-eluting stents:evidence from a meta-analysis of randomised trials.Euro Intervention,2011,7(8):985-994.
• [6]Kastrati A,Mehilli J,Pache J,et al.Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.N Engl J Med,2007,356(10):1030-1039.
• [7]Lagerqvist B,James SK,Stenestrand U,et al.Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.N Engl J Med,2007,356(10):1009-1019.
• [8]Virmani R,Gunglinmi G,Farb A,et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:should we be cautious?Circulation,2004,109(6):701-705.
• [9]Han Y,Xu B,Jing Q,et al.A randomized comparison of novel biodegradable polymer-and durable polymer-coated cobaltchromium sirolimus-eluting stents.JACC Cardiovasc Interv,2014,7(12):1352-1360.
• [10]Buszman PP,Orlik B,Trela B,et al.Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy:insights from a multicenter,propensity score-matched registry.Catheter Cardiovasc Interv,2013,82(3):155-162.
• [11]Stefanini GG,Byrne RA,Serruys PW,et al.Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at4 years in patients undergoing percutaneous coronary intervention:a pooled analysis of individual patient data from the ISAR-TEST 3,ISAR-TEST 4,and LEADERS randomized trials.Eur Heart J,2012,33(10):1214-1222.
• [12]Serruys PW,Farooq V,Kalesan B,et al.Improved safety and reduction in stent thrombosis asociated with biodegradable polymer-based biolimus-eluting stents versus durable polymerbased sirolimus-eluting stents in patients with coronary artery disease:final 5-year report of the LEADERS(Limus Eluted From A Durable Versus ERodable Stent Coating)randomized,noninferiority trial.JACC Cardiovasc Interv,2013,6(7):777-789.